{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T22:51:29Z","timestamp":1767135089930,"version":"build-2238731810"},"update-to":[{"DOI":"10.1002\/14651858.cd009144","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2011,12,7]],"date-time":"2011-12-07T00:00:00Z","timestamp":1323216000000}}],"reference-count":92,"publisher":"Wiley","issue":"12","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd009144.pub2","type":"journal-article","created":{"date-parts":[[2011,12,5]],"date-time":"2011-12-05T16:48:04Z","timestamp":1323103684000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Bisphosphonates for osteoporosis in primary biliary cirrhosis"],"prefix":"10.1002","volume":"2011","author":[{"given":"Jelena S","family":"Rudic","sequence":"first","affiliation":[{"name":"Clinic of Gastroenterology, Clinical Centre of Serbia; Department of Hepatology; Koste Todorovica 2 Belgrade Serbia 11000"},{"name":"Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 3344, Rigshospitalet, Copenhagen University Hospital; The Cochrane Hepato-Biliary Group; Blegdamsvej 9 Copenhagen Denmark DK-2100"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanja","family":"Giljaca","sequence":"additional","affiliation":[{"name":"Clinical Hospital Centre Rijeka; Department of Gastroenterology; Kresimirova 42 Rijeka Croatia 51000"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miodrag N","family":"Krstic","sequence":"additional","affiliation":[{"name":"Clinic of Gastroenterology, Clinical Centre of Serbia; Belgrade Serbia 11000"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Goran","family":"Bjelakovic","sequence":"additional","affiliation":[{"name":"Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 3344, Rigshospitalet, Copenhagen University Hospital; The Cochrane Hepato-Biliary Group; Blegdamsvej 9 Copenhagen Denmark DK-2100"},{"name":"Medical Faculty, University of Nis; Department of Internal Medicine; Zorana Djindjica 81 Nis Serbia 18000"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Gluud","sequence":"additional","affiliation":[{"name":"Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 3344, Rigshospitalet, Copenhagen University Hospital; The Cochrane Hepato-Biliary Group; Blegdamsvej 9 Copenhagen Denmark DK-2100"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,12,7]]},"reference":[{"key":"10.1002\/14651858.CD009144.pub2-BIB0002|cit1","doi-asserted-by":"crossref","unstructured":"Guanabens N Pares A Cyclical etidronate versus sodium fluoride for treatment of osteoporosis in primary biliary cirrhosis. Preliminary results after two years [abstract] Osteoporos International 1996 288","DOI":"10.1007\/BF02500690"},{"issue":"1","key":"10.1002\/14651858.CD009144.pub2-BIB0001|cit2","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0016-5085(97)70098-2","article-title":"Etidronate versus fluoride for treatment of osteopenia in primary biliary cirrhosis: preliminary results after 2 years","volume":"113","author":"Gua\u00f1abens","year":"1997","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1002\/14651858.CD009144.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1111\/j.1572-0241.2003.07639.x","article-title":"Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis","volume":"98","author":"Gua\u00f1abens","year":"2003","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD009144.pub2-BIB0004|cit4","doi-asserted-by":"crossref","unstructured":"Pares A Guanabens N Ros I Pons F Alvarez L Caballeria L Alendronate versus Etidronate for osteopenic patients with primary biliary cirrhosis: results after two years of treatment [abstract] Journal of Hepatology 2001 19","DOI":"10.1016\/S0168-8278(01)80934-X"},{"issue":"6","key":"10.1002\/14651858.CD009144.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/S0168-8278(00)80118-X","article-title":"Etidronate for osteoporosis in primary biliary cirrhosis: a randomized trial","volume":"33","author":"Lindor","year":"2000","journal-title":"Journal of Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD009144.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1016\/S0168-8278(10)60186-9","article-title":"Monthly ibandronate vs. weekly alendronate in the treatment of osteoporosis associated with primary biliary cirrhosis: Similar efficacy but different adherence","volume":"52","author":"Pares","year":"2010","journal-title":"Journal of Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD009144.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0168-8278(97)80048-7","article-title":"Cyclical etidronate in the prevention of bone loss in corticosteroid-treated primary biliary cirrhosis. A prospective, controlled pilot study","volume":"26","author":"Wolfhagen","year":"1997","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD009144.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"A10","DOI":"10.1016\/0300-2977(95)96973-L","article-title":"Cyclical etidronate in the prevention of corticosteroid-induced bone loss in primary biliary cirrhosis","volume":"47","author":"Wolfhagen","year":"1995","journal-title":"The Netherlands Journal of Medicine"},{"key":"10.1002\/14651858.CD009144.pub2-BIB0009|cit9","doi-asserted-by":"crossref","unstructured":"Zein CO Jorgensen RA Clarke B Lindor KD Alendronate improves bone mineral density in patients with primary biliary cirrhosis: randomized placebo-controlled trial Gastroenterology 2004 A671","DOI":"10.1002\/hep.20866"},{"issue":"4","key":"10.1002\/14651858.CD009144.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/hep.20866","article-title":"Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo-controlled trial","volume":"42","author":"Zein","year":"2005","journal-title":"Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD009144.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"239","DOI":"10.7326\/0003-4819-144-4-200602210-00005","article-title":"Zoledronic acid prevents bone loss after liver transplantation - a randomized, double-blind, placebo-controlled trial","volume":"144","author":"Crawford","year":"2006","journal-title":"Annals of Internal Medicine"},{"issue":"8","key":"10.1002\/14651858.CD009144.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1002\/lt.20466","article-title":"Alendronate in combination with calcium and vitamin D prevents bone loss after orthotopic liver transplantation: a prospective single-center study","volume":"11","author":"Millonig","year":"2005","journal-title":"Liver Transplantation"},{"issue":"2","key":"10.1002\/14651858.CD009144.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/S1386-6346(01)00123-1","article-title":"Cyclical etidronate for treatment of osteopenia in patients with cirrhosis of the liver","volume":"22","author":"Shiomi","year":"2002","journal-title":"Hepatology Research"},{"issue":"1","key":"10.1002\/14651858.CD009144.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/BF00298990","article-title":"Calcitonin and bisphosphonates treatment in bone loss after liver transplantation","volume":"57","author":"Valero","year":"1995","journal-title":"Calcified Tissue International"},{"issue":"1","key":"10.1002\/14651858.CD009144.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/hep.23637","article-title":"American Association for the Study of Liver Diseases endpoints conference: design and endpoints for clinical trials in primary biliary cirrhosis","volume":"52","author":"Silveira","year":"2010","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD009144.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"158","DOI":"10.2165\/00002018-199614030-00003","article-title":"Adverse effects of bisphosphonates: a\u00a0comparative review","volume":"14","author":"Adami","year":"1996","journal-title":"Drug Safety"},{"issue":"5","key":"10.1002\/14651858.CD009144.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/j.1365-2036.2004.02089.x","article-title":"Fracture risk of women with primary biliary cirrhosis: no increase compared with general population controls","volume":"20","author":"Boulton-Jones","year":"2004","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"8322","key":"10.1002\/14651858.CD009144.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/S0140-6736(83)91465-4","article-title":"Renal failure associated with intravenous diphosphonates","volume":"1","author":"Bounameaux","year":"1983","journal-title":"Lancet"},{"issue":"8","key":"10.1002\/14651858.CD009144.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.jclinepi.2007.10.007","article-title":"Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses","volume":"61","author":"Brok","year":"2008","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD009144.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/S0140-6736(98)09075-8","article-title":"Mortality after all major types of osteoporotic fracture in men and women: an observational study","volume":"353","author":"Nguyen","year":"1999","journal-title":"Lancet"},{"issue":"17","key":"10.1002\/14651858.CD009144.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJM200310233491721","article-title":"Renal failure with the use of zoledronic acid","volume":"349","author":"Chang","year":"2003","journal-title":"New England Journal of Medicine"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD009144.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/gut.50.suppl_1.i1","article-title":"Guidelines on the management of osteoporosis associated with chronic liver disease","volume":"50","author":"Collier","year":"2002","journal-title":"Gut"},{"key":"10.1002\/14651858.CD009144.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/BF01623184","article-title":"Hip fractures in the elderly: a world-wide projection","volume":"2","author":"Cooper","year":"1992","journal-title":"Osteoporosis International"},{"issue":"2A","key":"10.1002\/14651858.CD009144.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"12S","DOI":"10.1016\/S0002-9343(97)90022-X","article-title":"The crippling consequences of fractures and their impact on quality of life","volume":"103","author":"Cooper","year":"1997","journal-title":"American Journal of Medicine"},{"issue":"10","key":"10.1002\/14651858.CD009144.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.4065\/77.10.1031","article-title":"Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence?","volume":"77","author":"Cryer","year":"2002","journal-title":"Mayo Clinic Proceedings"},{"issue":"4","key":"10.1002\/14651858.CD009144.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0002-9343(01)01124-X","article-title":"Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs","volume":"112","author":"Cummings","year":"2002","journal-title":"American Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD009144.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/sim.4780060325","article-title":"Methods for combining randomized clinical trials: strengths and limitations","volume":"6","author":"DeMets","year":"1987","journal-title":"Statistics in Medicine"},{"issue":"3","key":"10.1002\/14651858.CD009144.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Controlled Clinical Trials"},{"issue":"1","key":"10.1002\/14651858.CD009144.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/0016-5085(89)90783-X","article-title":"Hepatic osteodystrophy. Static and dynamic bone histomorphometry and serum bone Gla-protein in 80 patients with chronic liver disease","volume":"96","author":"Diamond","year":"1989","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD009144.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jhep.2009.04.009","article-title":"EASL Clinical Practice Guidelines: management of cholestatic liver diseases","volume":"51","author":"European Association for the Study of the Liver","year":"2009","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD009144.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"1","key":"10.1002\/14651858.CD009144.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta7010","article-title":"How important are comprehensive literature searches and the assessment of trial quality in systematic reviews? Empirical study","volume":"7","author":"Egger","year":"2003","journal-title":"Health Technology Assessment"},{"issue":"899","key":"10.1002\/14651858.CD009144.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1126\/science.165.3899.1262","article-title":"Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo","volume":"165","author":"Fleisch","year":"1969","journal-title":"Science"},{"key":"10.1002\/14651858.CD009144.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"919","DOI":"10.2165\/00003495-199142060-00003","article-title":"Bisphosphonates: pharmacology and use in the treatment of tumour-induced hypercalcaemia and metastatic bone disease","volume":"42","author":"Fleisch","year":"1991","journal-title":"Drugs"},{"key":"10.1002\/14651858.CD009144.pub2-BIB0035|cit35","first-page":"S3","article-title":"Bisphosphonates in osteoporosis: an introduction","volume":"Suppl 3","author":"Fleisch","year":"1991","journal-title":"Osteoporosis International"},{"issue":"10","key":"10.1002\/14651858.CD009144.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/S1470-2045(10)70198-4","article-title":"Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial","volume":"11","author":"Gimsing","year":"2010","journal-title":"Lancet Oncology"},{"issue":"6","key":"10.1002\/14651858.CD009144.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/aje\/kwj069","article-title":"Bias in clinical intervention research","volume":"163","author":"Gluud","year":"2006","journal-title":"American Journal of Epidemiology"},{"issue":"4","key":"10.1002\/14651858.CD009144.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.jhep.2007.01.003","article-title":"Hepatology may have problems with putative surrogate outcome measures","volume":"46","author":"Gluud","year":"2007","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD009144.pub2-BIB0039|cit39","unstructured":"Gluud C Nikolova D Klingenberg SL Alexakis N Als-Nielsen B Colli A Cochrane Hepato-Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)) 2011, Issue 4. Art. No.: LIVER"},{"issue":"10","key":"10.1002\/14651858.CD009144.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1111\/j.1572-0241.2003.07639.x","article-title":"Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis","volume":"98","author":"Guanabens","year":"2003","journal-title":"American Journal of Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD009144.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jhep.2004.11.035","article-title":"Severity of cholestasis and advanced histological stage but not menopausal status are the major risk factors for osteoporosis in primary biliary cirrhosis","volume":"42","author":"Gua\u00f1abens","year":"2005","journal-title":"Journal of Hepatology"},{"issue":"7","key":"10.1002\/14651858.CD009144.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1053\/j.gastro.2010.02.016","article-title":"Low bone mass and severity of cholestasis affect fracture risk in patients with primary biliary cirrhosis","volume":"138","author":"Gua\u00f1abens","year":"2010","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1002\/14651858.CD009144.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD009144.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"10.1002\/14651858.CD009144.pub2-BIB0045|cit45","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011] The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org"},{"issue":"4","key":"10.1002\/14651858.CD009144.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1210\/jcem.87.4.8415","article-title":"Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents","volume":"87","author":"Hochberg","year":"2002","journal-title":"Journal of Clinical Endocrinology & Metabolism"},{"issue":"6","key":"10.1002\/14651858.CD009144.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/8756-3282(93)90310-7","article-title":"Rates of cancellous bone remodeling and turnover in osteopenia associated with primary biliary cirrhosis","volume":"14","author":"Hodgson","year":"1993","journal-title":"Bone"},{"key":"10.1002\/14651858.CD009144.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1136\/bmj.319.7211.670","article-title":"What is meant by intention to treat analysis? Survey of published randomised controlled trials","volume":"319","author":"Hollis","year":"1999","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"1","key":"10.1002\/14651858.CD009144.pub2-BIB0049|cit49","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001347","article-title":"Bisphosphonates for steroid induced osteoporosis","author":"Homik","year":"1999","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD009144.pub2-BIB0050|cit50","volume-title":"International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice1997 CFR & ICH Guidelines","volume":"1","author":"International Conference on Harmonisation Expert Working Group","year":"1997"},{"issue":"19","key":"10.1002\/14651858.CD009144.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1001\/archinternmed.2009.313","article-title":"Adverse events in randomized trials: neglected, restricted, distorted, and silenced","volume":"169","author":"Ioannidis","year":"2009","journal-title":"Archives of Internal Medicine"},{"issue":"6","key":"10.1002\/14651858.CD009144.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1007\/BF01622200","article-title":"Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group","volume":"4","author":"Kanis","year":"1994","journal-title":"Osteoporosis International"},{"issue":"8","key":"10.1002\/14651858.CD009144.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1359\/jbmr.080313","article-title":"Isoform of fibronectin mediates bone loss in patients with primary biliary cirrhosis by suppressing bone formation","volume":"23","author":"Kawelke","year":"2008","journal-title":"Journal of Bone and Mineral Research"},{"issue":"11","key":"10.1002\/14651858.CD009144.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"982","DOI":"10.7326\/0003-4819-135-11-200112040-00010","article-title":"Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses","volume":"135","author":"Kjaergard","year":"2001","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD009144.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1001\/jama.285.6.785","article-title":"Osteoporosis prevention, diagnosis, and therapy","volume":"285","author":"Klibanski","year":"2001","journal-title":"Journal of the American Medical Association"},{"issue":"3","key":"10.1002\/14651858.CD009144.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s11914-010-0018-z","article-title":"Bone densitometry and vertebral fracture assessment","volume":"8","author":"Lewiecki","year":"2010","journal-title":"Current Osteoporosis Reports"},{"issue":"1","key":"10.1002\/14651858.CD009144.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s11894-010-0166-4","article-title":"Bone disorders in chronic liver diseases","volume":"13","author":"Luxon","year":"2011","journal-title":"Current Gastroenterology Reports"},{"issue":"4","key":"10.1002\/14651858.CD009144.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/sim.698","article-title":"A comparison of methods to detect publication bias in meta-analysis","volume":"20","author":"Macaskill","year":"2001","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD009144.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1159\/000171456","article-title":"Osteoporosis in chronic liver disease: pathogenesis, risk factors, and management","volume":"12","author":"McCaughan","year":"1994","journal-title":"Digestive Diseases"},{"issue":"3","key":"10.1002\/14651858.CD009144.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/S0168-8278(01)00144-1","article-title":"Bone disease in primary biliary cirrhosis: independent indicators and rate of progression","volume":"35","author":"Menon","year":"2001","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD009144.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/jlac.18651330307","article-title":"[About the influence of chloracetyls on phosphorous acids] [author's translation]","volume":"133","author":"Menschutkin","year":"1865","journal-title":"Annalen der Chemie und Pharmacie"},{"issue":"7040","key":"10.1002\/14651858.CD009144.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1136\/bmj.312.7040.1181","article-title":"Primary biliary cirrhosis: epidemiology helping the clinician","volume":"312","author":"Metcalf","year":"1996","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"12","key":"10.1002\/14651858.CD009144.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.14219\/jada.archive.2005.0108","article-title":"Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper","volume":"136","author":"Migliorati","year":"2005","journal-title":"Journal of the American Dental Association"},{"key":"10.1002\/14651858.CD009144.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0140-6736(98)01085-X","article-title":"Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?","volume":"352","author":"Moher","year":"1998","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD009144.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/hep.21971","article-title":"Increased osteoclast formation and activity by peripheral blood mononuclear cells in chronic liver disease patients with osteopenia","volume":"47","author":"Olivier","year":"2008","journal-title":"Hepatology"},{"issue":"SuppI 1","key":"10.1002\/14651858.CD009144.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/S8756-3282(09)80009-4","article-title":"The use of bisphosphonates in the treatment of osteoporosis","volume":"13","author":"Papapoulos","year":"1992","journal-title":"Bone"},{"issue":"3","key":"10.1002\/14651858.CD009144.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.jhep.2006.06.007","article-title":"Treatment of bone disorders in liver disease","volume":"45","author":"Pares","year":"2006","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD009144.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa011807","article-title":"Intravenous zoledronic acid in postmenopausal women with low bone mineral density","volume":"346","author":"Reid","year":"2002","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD009144.pub2-BIB0069|cit69","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2011"},{"issue":"1","key":"10.1002\/14651858.CD009144.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1053\/jhep.2001.20533","article-title":"Hepatic osteodystrophy","volume":"33","author":"Rouillard","year":"2001","journal-title":"Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD009144.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1017\/S0266462303000552","article-title":"Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches","volume":"19","author":"Royle","year":"2003","journal-title":"International Journal of Technology Assessment in Health Care"},{"key":"10.1002\/14651858.CD009144.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1196\/annals.1346.041","article-title":"Bisphosphonates: from bench to bedside","volume":"1068","author":"Russell","year":"2006","journal-title":"Annals NewYork Academy of Sciences"},{"issue":"1","key":"10.1002\/14651858.CD009144.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.bone.2011.04.022","article-title":"Bisphosphonates: the first 40 years","volume":"49","author":"Russell","year":"2011","journal-title":"Bone"},{"issue":"5","key":"10.1002\/14651858.CD009144.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1056\/NEJM199807303390502","article-title":"Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis","volume":"339","author":"Saag","year":"1998","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD009144.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1016\/S0140-6736(06)68891-0","article-title":"Osteoporosis","volume":"37\u00a0","author":"Sambrook","year":"2006","journal-title":"Lancet"},{"issue":"5","key":"10.1002\/14651858.CD009144.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials","volume":"273","author":"Schulz","year":"1995","journal-title":"Journal of the American Medical Association"},{"issue":"1","key":"10.1002\/14651858.CD009144.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jocd.2005.10.001","article-title":"Hyperbilirubinemia is not a major contributing factor to altered bone mineral density in patients with chronic liver disease","volume":"9","author":"Smith","year":"2006","journal-title":"Journal of Clinical Densitometry"},{"issue":"6","key":"10.1002\/14651858.CD009144.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1053\/j.gastro.2006.09.012","article-title":"Fracture risk in people with primary biliary cirrhosis: a population-based cohort study","volume":"131","author":"Solaymani-Dodaran","year":"2006","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1002\/14651858.CD009144.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"755","DOI":"10.2165\/00002018-200730090-00003","article-title":"Safety considerations with bisphosphonates for the treatment of osteoporosis","volume":"30","author":"Strampel","year":"2007","journal-title":"Drug Safety"},{"issue":"11","key":"10.1002\/14651858.CD009144.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1002\/sim.1187","article-title":"How should meta-regression analyses be undertaken and interpreted?","volume":"21","author":"Thompson","year":"2002","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD009144.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1093\/ije\/dyn179","article-title":"Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses?","volume":"38","author":"Thorlund","year":"2009","journal-title":"International Journal of Epidemiology"},{"issue":"12","key":"10.1002\/14651858.CD009144.pub2-BIB0082|cit82","first-page":"1397","article-title":"Osteoporosis in patients with primary biliary cirrhosis","volume":"22","author":"Wariaghli","year":"2010","journal-title":"European Journal of Gastroenterology and Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD009144.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1210\/jcem.85.1.6267","article-title":"Antifracture efficacy of antiresorptive agents are related to changes in bone density","volume":"85","author":"Wasnich","year":"2000","journal-title":"Journal of Clinical Endocrinology & Metabolism"},{"issue":"1","key":"10.1002\/14651858.CD009144.pub2-BIB0084|cit84","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001155.pub2","article-title":"Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women","author":"Wells","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD009144.pub2-BIB0085|cit85","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003376.pub3","article-title":"Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women","author":"Wells","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD009144.pub2-BIB0086|cit86","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004523.pub3","article-title":"Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women","author":"Wells","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD009144.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jclinepi.2007.03.013","article-title":"Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis","volume":"61","author":"Wetterslev","year":"2008","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD009144.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/1471-2288-9-86","article-title":"Estimating required information size by quantifying diversity in random-effects model meta-analyses","volume":"9","author":"Wetterslev","year":"2009","journal-title":"BMC Medical Research Methodology"},{"key":"10.1002\/14651858.CD009144.pub2-BIB0089|cit89","first-page":"1","article-title":"Assessment of fracture risk and its application to screening for postmenopausal osteoporosis","volume":"843","author":"World Health Organization Study Group","year":"1994","journal-title":"World Health Organization Technical Report Series"},{"key":"10.1002\/14651858.CD009144.pub2-BIB0090|cit90","unstructured":"World Health Organization FRAX WHO Fracture Risk Assessment Tool www.shef.ac.uk\/FRAX\/"},{"issue":"4","key":"10.1002\/14651858.CD009144.pub2-BIB0091|cit91","first-page":"629","article-title":"Management of osteoporosis in primary biliary cirrhosis","volume":"14","author":"Wolfhagen","year":"2000","journal-title":"Baillieres Clinical Gastroenterology"},{"issue":"7644","key":"10.1002\/14651858.CD009144.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1136\/bmj.39465.451748.AD","article-title":"Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study","volume":"336","author":"Wood","year":"2008","journal-title":"BMJ (Clinical Research Ed.)"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD009144.pub2\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T17:01:36Z","timestamp":1758301296000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD009144.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Hepato-Biliary Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2011,12,7]]},"references-count":92,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2011,12]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd009144.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12,7]]}}}